Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis.

Autor:	Cardoso RN; Department of Internal Medicine , University of Miami/Jackson Memorial Hospital , Miami, Florida , USA., Benjo AM; Department of Cardiology , Ochsner Medical Center , New Orleans, Louisiana , USA., DiNicolantonio JJ; Saint Luke's Mid America Heart Institute , Kansas City, Missouri , USA., Garcia DC; Department of Internal Medicine , University of Miami/Jackson Memorial Hospital , Miami, Florida , USA., Macedo FY; Department of Cardiology , Baylor College of Medicine and Michael E. DeBakey VA Medical Center , Houston, Texas , USA., El-Hayek G; St.Luke's Roosevelt Medical Center , New York, New York , USA., Nadkarni GN; Nephrology Department , Mount Sinai Hospital , New York, New York , USA., Gili S; Department of Cardiology , University of Turin , Turin , Italy., Iannaccone M; Department of Cardiology , University of Turin , Turin , Italy., Konstantinidis I; Nephrology Department , Mount Sinai Hospital , New York, New York , USA., Reilly JP; Department of Cardiology , Ochsner Medical Center , New Orleans, Louisiana , USA.
Jazyk:	angličtina
Zdroj:	Open heart [Open Heart] 2015 Jun 30; Vol. 2 (1), pp. e000248. Date of Electronic Publication: 2015 Jun 30 (Print Publication: 2015).
DOI:	10.1136/openhrt-2015-000248
Abstrakt:	Background: Dual antiplatelet therapy is the standard of care after coronary stent placement but increases the bleeding risk. The effects of proton pump inhibitors (PPIs) on clopidogrel metabolism have been described, but the clinical significance is not yet definitive. We aimed to do an updated meta-analysis comparing outcomes in patients receiving clopidogrel with and without PPIs. Methods: We systematically searched PubMed, Scopus and the Cochrane Central Register of Controlled Trials for randomised controlled trials (RCTs) and controlled observational studies in patients taking clopidogrel stratified by concomitant PPI use. Heterogeneity was examined with the Cochran Q test and I(2) statistics; p values inferior to 0.10 and I(2) >25% were considered significant for heterogeneity. Results: We included 39 studies with a total of 214 851 patients, of whom 73 731 (34.3%) received the combination of clopidogrel and a PPI. In pooled analysis, all-cause mortality, myocardial infarction, stent thrombosis and cerebrovascular accidents were more common in patients receiving both drugs. However, among 23 552 patients from eight RCTs and propensity-matched studies, there were no significant differences in mortality or ischaemic events between groups. The use of PPIs in patients taking clopidogrel was associated with a significant reduction in the risk of gastrointestinal bleeding. Conclusions: The results of our meta-analysis suggest that PPIs are a marker of increased cardiovascular risk in patients taking clopidogrel, rather than a direct cause of worse outcomes. The pharmacodynamic interaction between PPIs and clopidogrel most likely has no clinical significance. Furthermore, PPIs have the potential to decrease gastrointestinal bleeding in clopidogrel users.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu